ArticleExperimental hematology & oncology2023

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases.

Haowei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.